Enterprise Value
-111.8M
Cash
184.7M
Avg Qtr Burn
-25.39M
Short % of Float
3.64%
Insider Ownership
0.21%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KIN-7136 (MEK inhibitor) +/- exarafenib Details Solid tumor/s, Non-small cell lung carcinoma | Phase 1 Update | |
Phase 1 Update | ||
exarafenib (KN-2787) +/- binimetinib Details Cancer, Solid tumor/s, Melanoma | Phase 1 Update |